In GC, tumor cells in metastatic sites could secrete TGF- β1 to prompt the production of cancer-associated fibroblasts-derived LOX, which may explain the higher fold-change of LOX under the treatment of TGF-β1 [45]. The gene discussed is LOX; the disease is gastric cancer.